http://orcid.org/0000-0003-3803-3046
References
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–267.
- Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin 2008;24:1763–1770.
- Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis. Ophthalmology 2014;121:2081–2090.
- Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–1279.
- European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona, Italy: PubliComm Srl; 2014.
- Wilson LA. To preserve or not to preserve, is that the question? Br J Ophthalmol 1996;80:583–584.
- Kim MS, Choi CY, Kim JM, et al. Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br J Ophthalmol 2008;92:1518–1521.
- Baudouin C. The ocular surface in glaucoma. Cornea 2009;28:S14–S19.
- Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618–621.
- Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000;32:3–8.
- Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998;17:419–425.
- Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490–496.
- Hamard P, Debbasch C, Blondin C, et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J Fr Ophtalmol 2002;25:777–784.
- Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefe's Arch Clin Exp Ophthalmol 2003;241:1037–1043.
- Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716–726.
- Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341–349.
- De Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefe's Arch Clin Exp Ophthalmol 1994;232:221–224.
- Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39–42.
- Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119–126.
- Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2003;19:37–44.
- El Ameen A, Vandermeer G, K Khanna R, et al. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol 2018;29:645–653.
- Misiuk-Hojlo M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol 2019;29:210–215.
- Nuzzi R, Finazzo C, Vercelli A, et al. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long- term topical treatment: an immunohistochemical and ultrastructural study. Graefe’s Arch Clin Exp Ophthalmol 1995;233:154–162.
- Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312–334.
- Boyles JV, Kent JS. Storage and delivery of multi-dose, preservative-free pharmaceuticals. US6450994B1; 2002.
- De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619–630.